Long-Term Real-World Evaluation of Abrocitinib in Moderate-to-Severe Atopic Dermatitis Across a Diverse Patient Population in a Multi-site Hospital System | Synapse
March 3, 2026
Long-Term Real-World Evaluation of Abrocitinib in Moderate-to-Severe Atopic Dermatitis Across a Diverse Patient Population in a Multi-site Hospital System
Key Points
Abrocitinib significantly improves symptoms in moderate-to-severe atopic dermatitis patients.
The analysis included a diverse patient population across multiple sites, reflecting real-world effectiveness.
Observational assessment across a multi-site hospital system provided insights into long-term outcomes.
These findings support the need for continued use of abrocitinib in varied clinical settings.